These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 23221337)

  • 1. Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.
    Chang T; Krisman K; Theobald EH; Xu J; Akutagawa J; Lauchle JO; Kogan S; Braun BS; Shannon K
    J Clin Invest; 2013 Jan; 123(1):335-9. PubMed ID: 23221337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.
    Jessen WJ; Miller SJ; Jousma E; Wu J; Rizvi TA; Brundage ME; Eaves D; Widemann B; Kim MO; Dombi E; Sabo J; Hardiman Dudley A; Niwa-Kawakita M; Page GP; Giovannini M; Aronow BJ; Cripe TP; Ratner N
    J Clin Invest; 2013 Jan; 123(1):340-7. PubMed ID: 23221341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm.
    Kong G; Wunderlich M; Yang D; Ranheim EA; Young KH; Wang J; Chang YI; Du J; Liu Y; Tey SR; Zhang X; Juckett M; Mattison R; Damnernsawad A; Zhang J; Mulloy JC; Zhang J
    J Clin Invest; 2014 Jun; 124(6):2762-73. PubMed ID: 24812670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice.
    Lyubynska N; Gorman MF; Lauchle JO; Hong WX; Akutagawa JK; Shannon K; Braun BS
    Sci Transl Med; 2011 Mar; 3(76):76ra27. PubMed ID: 21451123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Normal hematopoiesis and neurofibromin-deficient myeloproliferative disease require Erk.
    Staser K; Park SJ; Rhodes SD; Zeng Y; He YZ; Shew MA; Gehlhausen JR; Cerabona D; Menon K; Chen S; Sun Z; Yuan J; Ingram DA; Nalepa G; Yang FC; Clapp DW
    J Clin Invest; 2013 Jan; 123(1):329-34. PubMed ID: 23221339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Combination of rhBMP-2 (Recombinant Human Bone Morphogenetic Protein-2) and MEK (MAP Kinase/ERK Kinase) Inhibitor PD0325901 Increases Bone Formation in a Murine Model of Neurofibromatosis Type I Pseudarthrosis.
    El-Hoss J; Cheng T; Carpenter EC; Sullivan K; Deo N; Mikulec K; Little DG; Schindeler A
    J Bone Joint Surg Am; 2014 Jul; 96(14):e117. PubMed ID: 25031379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retroviral mutagenesis screen reveals strong cooperation between Bcl11a overexpression and loss of the Nf1 tumor suppressor gene.
    Yin B; Delwel R; Valk PJ; Wallace MR; Loh ML; Shannon KM; Largaespada DA
    Blood; 2009 Jan; 113(5):1075-85. PubMed ID: 18948576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NF1 deletion generates multiple subtypes of soft-tissue sarcoma that respond to MEK inhibition.
    Dodd RD; Mito JK; Eward WC; Chitalia R; Sachdeva M; Ma Y; Barretina J; Dodd L; Kirsch DG
    Mol Cancer Ther; 2013 Sep; 12(9):1906-17. PubMed ID: 23858101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.
    Wiesner SM; Geurts JL; Diers MD; Bergerson RJ; Hasz DE; Morgan KJ; Largaespada DA
    Am J Hematol; 2011 Jul; 86(7):579-85. PubMed ID: 21681782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML.
    Yoshimi A; Balasis ME; Vedder A; Feldman K; Ma Y; Zhang H; Lee SC; Letson C; Niyongere S; Lu SX; Ball M; Taylor J; Zhang Q; Zhao Y; Youssef S; Chung YR; Zhang XJ; Durham BH; Yang W; List AF; Loh ML; Klimek V; Berger MF; Stieglitz E; Padron E; Abdel-Wahab O
    Blood; 2017 Jul; 130(4):397-407. PubMed ID: 28576879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitotic recombination and compound-heterozygous mutations are predominant NF1-inactivating mechanisms in children with juvenile myelomonocytic leukemia and neurofibromatosis type 1.
    Steinemann D; Arning L; Praulich I; Stuhrmann M; Hasle H; Stary J; Schlegelberger B; Niemeyer CM; Flotho C
    Haematologica; 2010 Feb; 95(2):320-3. PubMed ID: 20015894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency.
    Sachs Z; Been RA; DeCoursin KJ; Nguyen HT; Mohd Hassan NA; Noble-Orcutt KE; Eckfeldt CE; Pomeroy EJ; Diaz-Flores E; Geurts JL; Diers MD; Hasz DE; Morgan KJ; MacMillan ML; Shannon KM; Largaespada DA; Wiesner SM
    Haematologica; 2016 Oct; 101(10):1190-1199. PubMed ID: 27418650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta common receptor inactivation attenuates myeloproliferative disease in Nf1 mutant mice.
    Kim A; Morgan K; Hasz DE; Wiesner SM; Lauchle JO; Geurts JL; Diers MD; Le DT; Kogan SC; Parada LF; Shannon K; Largaespada DA
    Blood; 2007 Feb; 109(4):1687-91. PubMed ID: 17090653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developmental dosing with a MEK inhibitor (PD0325901) rescues myopathic features of the muscle-specific but not limb-specific Nf1 knockout mouse.
    Summers MA; Vasiljevski ER; Mikulec K; Peacock L; Little DG; Schindeler A
    Mol Genet Metab; 2018 Apr; 123(4):518-525. PubMed ID: 29477258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Germline Neurofibromin 1 mutation enhances the anti-tumour immune response and decreases juvenile myelomonocytic leukaemia tumourigenicity.
    Wang W; Li X; Qin X; Miao Y; Zhang Y; Li S; Yao R; Yang Y; Yu L; Zhu H; Song L; Mao S; Wang X; Chen J; Feng H; Li Y
    Br J Haematol; 2023 Jul; 202(2):328-343. PubMed ID: 37144690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review.
    Patnaik MM; Lasho T
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):460-464. PubMed ID: 33275673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential clinical use of azacitidine and MEK inhibitor combination therapy in PTPN11-mutated juvenile myelomonocytic leukemia.
    Pasupuleti SK; Chao K; Ramdas B; Kanumuri R; Palam LR; Liu S; Wan J; Annesley C; Loh ML; Stieglitz E; Burke MJ; Kapur R
    Mol Ther; 2023 Apr; 31(4):986-1001. PubMed ID: 36739480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.
    de la Croix Ndong J; Stevens DM; Vignaux G; Uppuganti S; Perrien DS; Yang X; Nyman JS; Harth E; Elefteriou F
    J Bone Miner Res; 2015 Jan; 30(1):55-63. PubMed ID: 25043591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of hematopoietic lineage involvement in children with neurofibromatosis type 1 and malignant myeloid disorders.
    Miles DK; Freedman MH; Stephens K; Pallavicini M; Sievers EL; Weaver M; Grunberger T; Thompson P; Shannon KM
    Blood; 1996 Dec; 88(11):4314-20. PubMed ID: 8943868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biallelic inactivation of the NF1 tumour suppressor gene in juvenile myelomonocytic leukaemia: Genetic evidence of driver function and implications for diagnostic workup.
    Ramamoorthy S; Lebrecht D; Schanze D; Schanze I; Wieland I; Andrieux G; Metzger P; Hess M; Albert MH; Borkhardt A; Bresters D; Buechner J; Catala A; De Haas V; Dworzak M; Erlacher M; Hasle H; Jahnukainen K; Locatelli F; Masetti R; Stary J; Turkiewicz D; Vinci L; Wlodarski MW; Yoshimi A; Boerries M; Niemeyer CM; Zenker M; Flotho C
    Br J Haematol; 2024 Feb; 204(2):595-605. PubMed ID: 37945316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.